Q4 2024 Lifecore Biomedical Inc Earnings Call Transcript
Key Points
- Lifecore Biomedical Inc (LFCR) reported a 24.2% increase in revenues for fiscal 2024, reaching $128.3 million.
- The company achieved a significant improvement in gross profit, which increased by 49.5% to $41.9 million.
- Adjusted EBITDA for the full year of 2024 increased by 82%, reaching $20.2 million.
- Lifecore Biomedical Inc (LFCR) is now current with all its SEC filings, resolving previous delays.
- The company has a strong outlook for its commercial business and is actively engaging with multinational pharmaceutical companies for new opportunities.
- Lifecore Biomedical Inc (LFCR) faced significant delays in public filings due to divestitures and restatements.
- The company expects flat revenue growth for fiscal year 2025, influenced by a key customer's inventory rebalancing and the loss of a small commercial customer.
- Gross margins are expected to decline by approximately 225 to 275 basis points in fiscal year 2025 due to a mix shift towards more commercial revenues and increased depreciation costs.
- The company continues to incur restructuring and reorganization costs, which are expected to be between $5.5 million to $6.5 million in fiscal year 2025.
- Lifecore Biomedical Inc (LFCR) implemented a strategic reduction in workforce, affecting 46 employees or 9% of its employee base.
Greetings, and welcome to the Lifecore Biomedical Q4 and full-year 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, Stephanie Diaz, Investor Relations. Stephanie, please go ahead.
Good morning, and thank you for joining us today to discuss Lifecore Biomedical fourth quarter and full year fiscal 2024 earnings results. Hosting the call today from the company are Paul Josephs, President and CEO; and John Morberg, Chief Financial Officer.
Before we begin today, we'd like to remind everyone of the Safe Harbor statement. Certain statements made in the course of this conference call contain forward looking statements. It is important to note that the company's actual results could differ materially from those projected in such forward-looking statements.
Additional information concerning risk factors that could cause actual results to differ materially from those in the forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
